arrow
S

Suma P. Shankar

hopital universitaire robert-debre - aphp
H指数:26
被引数:3,640

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

De novo variants in KDM2A cause a syndromic neurodevelopmental disorder

KDM2A基因中的全新变异导致一种综合征性神经发育障碍

2026-01-011
OA
A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder (vol 24, pg 1567, 2022)
2022-10-011
OAAI
A novel DPH5-related diphthamide-deficiency syndrome causing embryonic lethality or profound neurodevelopmental disorder
2022-07-0110
OAAI
Quantitative brain MRI morphology in severe and attenuated forms of mucopolysaccharidosis type I

严重和减弱形式的I型粘多糖贮积症的定量脑MRI形态学

2022-02-017
OAAI
Semaphorin-Plexin Signaling: From Axonal Guidance to a New X-Linked Intellectual Disability Syndrome
2022-01-018
OAAI
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results
2021-07-1128
OAAI
Project Baby Bear: Rapid precision care incorporating rWGS in 5 California children's hospitals demonstrates improved clinical outcomes and reduced costs of care
2021-07-01154
OAAI
Individual patient responses to eliglustat in treatment-naive adults with Gaucher disease type 1: Final data from the phase 3 ENGAGE trial
2020-02-010
PREAI
Low-dose agalsidase beta treatment in male pediatric patients with Fabry disease: A 5-year randomized controlled trial

低剂量半乳糖苷酶 β 治疗小儿法布里病男性患者的5年随机对照试验

2019-05-0128
OAAI
Outcomes after 18 months of eliglustat therapy in treatment-naive adults with Gaucher disease type 1: The phase 3 ENGAGE trial
2017-10-0365
OAAI
Long-term results of ENGAGE: a phase 3, randomized, double blind, placebo-controlled, multi center study investigating the efficacy and safety of eliglustat in adults with type 1 Gaucher disease
2017-01-013
PREAI